Is PBYI or PCSA more undervalued in 2026?

CirclFi compares Puma Biotechnology Inc (PBYI) and Processa Pharmaceuticals, Inc. (PCSA) using 13 institutional-grade valuation models. PBYI has a Quality of Company score of 8.4/10 while PCSA scores 3.7/10.

Which is a better buy — PBYI or PCSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PBYI and PCSA valuations compare?

PBYI at $7.24 and PCSA at $2.64 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PBYI vs PCSA Valuation Comparison 2026 — Intrinsic Value Analysis

PBYI

Biotechnology

Puma Biotechnology Inc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$7.24

Last close

Models

12/13

Active

PCSA

Biotechnology

Processa Pharmaceuticals, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$2.64

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	PBYI Fair Value	PBYI Upside	PCSA Fair Value	PCSA Upside
Bayesian DCF	Intrinsic	$6.50	-10.2%	$1.04	-60.5%
Earnings Power Value	Intrinsic	$4.28	-40.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.67	-49.3%	$0.20	-93.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PBYI vs PCSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PBYI vs PCSA — Which Stock Is More Undervalued?

PBYI scores higher with a 8.4/10 quality rating vs PCSA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Puma Biotechnology Inc (PBYI) and Processa Pharmaceuticals, Inc. (PCSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PBYI currently trades at $7.24 with a QOC of 8.4/10, while PCSA trades at $2.64 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).